IQVIA Holdings, Inc.
IQV
$235.02
-1.16%
IQVIA Holdings Inc. is a global leader in clinical research and technology solutions for the life science industry, formed in 2016 from the merger of Quintiles and IMS Health. It combines outsourced clinical development services with extensive healthcare data and analytics, serving biopharmaceutical firms, providers, payers, and policymakers. The company is a dominant player in the contract research organization (CRO) and healthcare analytics space, leveraging its unique data assets to drive drug development and commercialization. Current investor attention centers on IQVIA's ability to sustain revenue growth amid a mixed biotech funding environment, with recent news highlighting competitive dynamics in the weight-loss drug market that could impact its client base.…
IQV
IQVIA Holdings, Inc.
$235.02
Related headlines
IQV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IQVIA Holdings, Inc.'s 12-month outlook, with a consensus price target around $272.94 and implied upside of +16.1% versus the current price.
Average Target
$272.94
0 analysts
Implied Upside
+16.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$240 - $300
Analyst target range
IQVIA is covered by 19 analysts, with a consensus recommendation of 'strong buy' (mean rating 1.45 on a 1-5 scale). The average target price is $232.00, implying approximately 11.5% upside from the current price of $208.05. The distribution shows 10 analysts with strong buy or buy ratings, and recent upgrades from firms like TD Cowen (Hold to Buy) and Barclays (Equal Weight to Overweight) indicate positive sentiment. The target price range spans from a low of $200.00 to a high of $284.00. The high target of $284 suggests potential upside of 36.5%, likely assuming multiple expansion and accelerating growth from new drug development catalysts. The low target of $200 implies a slight downside of 3.9%, possibly pricing in margin compression or slower revenue growth. The wide spread ($84) indicates high uncertainty among analysts, but the recent upgrade momentum and strong buy consensus suggest that the majority see a favorable risk/reward. The limited number of downgrades (e.g., Morgan Stanley from Overweight to Equal Weight) is offset by multiple upgrades, reinforcing the bullish outlook.
Drowning in data?
Find the real signal!
Bulls vs Bears: IQV Investment Factors
IQVIA presents a balanced risk/reward profile. The bull case is supported by accelerating revenue growth (8.41% YoY), a strong analyst consensus (strong buy, average target $232), and an attractive forward P/E of 14.68x that suggests earnings growth is not fully priced in. The bear case centers on margin compression (gross margin down to 32.64%), high leverage (D/E 2.49), and a PEG ratio of 6.34x that implies premium pricing. The most critical tension is whether IQVIA can sustain its revenue growth trajectory while stabilizing or improving margins. If the company delivers on earnings expectations (estimated EPS of $19.59), the forward P/E compression could drive significant upside. However, any disappointment in growth or further margin erosion could lead to multiple contraction. Currently, the evidence slightly favors the bull case given the strong analyst upgrades and reasonable forward valuation, but the margin trend warrants close monitoring.
Bullish
- Strong Revenue Growth Trajectory: IQVIA's Q1 2026 revenue grew 8.41% YoY to $4.151 billion, with accelerating quarterly growth from $3.829B in Q1 2025 to $4.364B in Q4 2025. This consistent expansion demonstrates robust demand for clinical research and analytics services.
- Analyst Consensus Strong Buy: 19 analysts rate IQVIA a 'strong buy' with a mean rating of 1.45/5. The average target price of $232 implies 11.5% upside, while the high target of $284 suggests 36.5% potential. Recent upgrades from TD Cowen and Barclays reinforce positive sentiment.
- Attractive Forward Valuation: The forward P/E of 14.68x is significantly lower than the trailing P/E of 28.50x, implying the market expects substantial earnings growth. This forward multiple is reasonable for a company with 8.4% revenue growth and strong free cash flow generation.
- Robust Free Cash Flow Generation: IQVIA generated $2.545 billion in trailing twelve-month free cash flow, with $491 million in Q1 2026 alone. This strong cash flow provides financial flexibility to service debt and invest in growth despite a debt-to-equity ratio of 2.49.
Bearish
- Margin Compression Trend: Gross margin declined from 34.90% in Q4 2024 to 32.64% in Q1 2026, and operating margin fell from 16.78% in Q4 2025 to 12.38% in Q1 2026. This compression suggests rising costs or pricing pressure that could pressure profitability.
- High Debt-to-Equity Ratio: With a debt-to-equity ratio of 2.49, IQVIA carries significant leverage. While free cash flow covers interest expenses (interest expense of $192M in Q1 2026), the high debt load increases financial risk, especially if interest rates remain elevated.
- Elevated PEG Ratio Indicates Overvaluation: The PEG ratio of 6.34x suggests the stock is priced at a premium relative to its earnings growth rate. This implies that the market is pricing in aggressive future growth, leaving little room for error if growth disappoints.
- Underperformance vs. S&P 500: IQVIA's 1-year price return of +3.6% significantly lags the S&P 500's +16.47%. Despite a strong 3-month rally of 28.2%, the stock has underperformed on a relative strength basis over 1-year (-12.87%), indicating persistent negative sentiment.
IQV Technical Analysis
IQVIA's price trend over the past year shows a modest gain of 3.6%, but the stock has experienced significant volatility, with a 52-week range of $154.50 to $247.05. As of July 24, 2026, the stock closed at $208.05, which is approximately 54% of the 52-week range, indicating it is trading closer to the midpoint. This positioning suggests a recovery from the lows but still below the highs, reflecting a cautious market sentiment. The 1-year price change of +3.6% underperforms the S&P 500's +16.47%, highlighting relative weakness. Short-term momentum is strongly positive, with a 1-month price change of +12.08% and a 3-month change of +28.20%, both significantly outpacing the S&P 500's 0.78% and 3.5% respectively. This acceleration from the longer-term trend suggests a potential reversal or mean reversion, as the stock has rallied sharply from its February lows near $162. The relative strength index (RSI) is not provided, but the volume data (1,089,778 shares) and the short ratio of 3.06 indicate moderate bearish sentiment. The 52-week low of $154.50 serves as key support, while the 52-week high of $247.05 is the primary resistance. A breakout above $247 would signal a resumption of the long-term uptrend, while a breakdown below $154.5 could indicate further downside. The beta of 1.2 implies IQVIA is 20% more volatile than the market, meaning it amplifies market moves, which is important for risk management.
Beta
1.20
1.20x market volatility
Max Drawdown
-35.9%
Largest decline past year
52-Week Range
$155-$251
Price range past year
Annual Return
+26.4%
Cumulative gain past year
| Period | IQV Return | S&P 500 |
|---|---|---|
| 1m | +15.7% | +0.2% |
| 3m | +49.0% | +3.7% |
| 6m | +2.1% | +8.0% |
| 1y | +26.4% | +18.2% |
| ytd | +4.3% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IQV Fundamental Analysis
IQVIA's revenue trajectory shows steady growth, with Q1 2026 revenue of $4.151 billion, up 8.41% year-over-year from $3.829 billion in Q1 2025. The multi-quarter trend reveals accelerating growth: Q1 2025 revenue was $3.829 billion, Q2 2025 $4.017 billion, Q3 2025 $4.100 billion, and Q4 2025 $4.364 billion. The Research and Development Solutions segment contributed $2.397 billion in the most recent quarter, indicating that clinical services remain the primary growth driver. The company is profitable, with Q1 2026 net income of $274 million and a gross margin of 32.64%. However, gross margin has declined from 34.90% in Q4 2024 to 32.64% in Q1 2026, suggesting some margin compression. Operating margin was 12.38% in Q1 2026, down from 16.77% in Q4 2025, but this may reflect seasonal or investment-related factors. The net margin of 6.60% is relatively low for the healthcare services industry, but the company is generating positive earnings. IQVIA's balance sheet shows a debt-to-equity ratio of 2.49, which is elevated, indicating significant leverage. However, free cash flow (FCF) is strong at $2.545 billion on a trailing twelve-month basis, and the company generated $491 million in FCF in Q1 2026 alone. The current ratio of 0.75 suggests tight liquidity, but the strong cash flow generation provides flexibility. Return on equity (ROE) is 20.91%, reflecting efficient use of equity capital despite the high debt load.
Quarterly Revenue
$4.2B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
32.6%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IQV Overvalued?
Since IQVIA has positive net income ($274 million in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 28.50x, while the forward P/E is 14.68x, implying that the market expects significant earnings growth. The gap between trailing and forward P/E suggests that analysts anticipate a sharp increase in earnings, which is consistent with the estimated EPS of $19.59 for the next fiscal year. Compared to the industry average (not provided), IQVIA's P/E of 28.5x appears elevated relative to the broader market, but the forward P/E of 14.68x is more reasonable. The price-to-sales (P/S) ratio of 2.38x is moderate for a healthcare services company. Historically, IQVIA's trailing P/E has ranged from around 20x to over 40x over the past few years. The current trailing P/E of 28.5x is near the lower end of its historical range, suggesting that the stock is not overvalued relative to its own history. The PEG ratio of 6.34x indicates that the stock is priced at a premium to its growth rate, but this may reflect the expected earnings rebound.
PE
28.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IQVIA's primary financial risk stems from its high debt-to-equity ratio of 2.49, which amplifies earnings volatility and interest expense sensitivity. In Q1 2026, interest expense was $192 million, consuming a significant portion of operating income ($514 million). While free cash flow of $2.545 billion TTM provides coverage, any downturn in revenue could strain debt servicing. Additionally, gross margin has declined from 34.90% in Q4 2024 to 32.64% in Q1 2026, and operating margin dropped from 16.78% to 12.38% over the same period, indicating potential cost inflation or pricing pressure. The current ratio of 0.75 suggests tight liquidity, though strong cash flow mitigates this concern. Revenue concentration in the R&D Solutions segment ($2.397 billion in Q1 2026) exposes the company to biotech funding cycles.
Market & Competitive Risks: IQVIA trades at a trailing P/E of 28.50x, which is elevated relative to the broader market but near the lower end of its historical range. The forward P/E of 14.68x implies aggressive earnings growth expectations, leaving the stock vulnerable to multiple compression if growth disappoints. With a beta of 1.2, IQVIA is 20% more volatile than the market, amplifying downside in bear markets. Competitive risks include pressure from other large CROs like LabCorp (Covance) and Thermo Fisher (PPD), as well as the potential for biopharma clients to insource clinical trials. Recent news about Eli Lilly's weight-loss drug challenges highlights the competitive dynamics in high-growth therapeutic areas that could impact IQVIA's client base.
Worst-Case Scenario: In a severe downturn, IQVIA could face a combination of revenue deceleration (e.g., below 5% growth), further margin compression, and multiple contraction. If the stock were to retest its 52-week low of $154.50, that would represent a 25.7% decline from the current price of $208.05. The historical max drawdown of -35.87% suggests that in an extreme scenario, the stock could fall to approximately $133.40, implying a potential loss of 35.9% from current levels. This could be triggered by a prolonged biotech funding freeze, loss of a major client, or a broader market correction that disproportionately impacts high-beta growth stocks.